GLP-1 is released from the gut in response to food intake and plays a crucial role in regulating blood sugar levels, appetite, and metabolism
"The barriers to use and reuse are getting so low that it's a little hard to project." As with many things relating to GLP-1s, consumer behavior is far outpacing research about the effects of their use in different situations
With her expertise and care, you can feel confident in your journey toward healthier living
The Evidence Here is exactly what the SELECT trial found: 17,604 participants enrolled, all with established cardiovascular disease, BMI of 27 or greater, and no diabetes Primary MACE event rate: 6.5 percent in the semaglutide group versus 8.0 percent in the placebo group Hazard ratio of 0.80 means a 20 percent relative reduction in the risk of heart attack, stroke, or cardiovascular death 95 percent confidence interval: 0.72 to 0.90, meaning the true effect falls within that range with high certainty P value less than 0.001, which is statistically decisive Mean follow-up: 39.8 months Mean weight loss with semaglutide: 9.4 percent of body weight Serious adverse events leading to discontinuation: 16.6 percent in the semaglutide group versus 8.2 percent in the placebo group That last number is a bit concerning